Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ANI Pharmaceuticals has completed the acquisition of the NDAs for purified corticotropin gel and corticotropin zinc hydroxide from Merck for $75m in cash and a percentage of future net sales.
Subscribe to our email newsletter
The acquisition was funded through cash on hand.
The assets were acquired from a Dutch subsidiary of Merck by ANI Pharmaceuticals C.V., a Netherlands based wholly owned indirect subsidiary of ANI.
ANI Pharmaceuticals president and CEO Arthur Przybyl said: "Having now closed the acquisition of the corticotrophin NDAs, we look forward to advancing our re-commercialization plan."